Evidence map›Paper›PMID 28275519›Full record

ArticleArab journal of urology2017

Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial.

Amr Fawzi, Mostafa Kamel, Emad Salem, Esam Desoky, Mohamed Omran, Hazem Elgalaly, Ahmed Sakr, Aref Maarouf, Salem Khalil

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arab journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amr FawziDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Mostafa KamelDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Emad SalemDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Esam DesokyDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Mohamed OmranDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Hazem ElgalalyDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Ahmed SakrDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Aref MaaroufDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Salem KhalilDepartment of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the additive effect of sildenafil citrate to tamsulosin in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) in men with or without erectile dysfunction (ED). PATIENTS AND

methodsIn all, 150 men with untreated LUTS/BPH with or without ED were randomised to receive sildenafil 25 mg once daily (OD) or placebo OD (night time) combined with tamsulosin 0.4 mg OD (day time) for 6 months. Changes from pre-treatment scores in International Prostate Symptom Score (IPSS), IPSS-quality of life (QoL) score, maximum urinary flow rate (

resultsGroup A comprised of men who received tamsulosin and sildenafil (75 men), whilst those in Group B received tamsulosin and placebo (75). The IPSS was significantly improved in Group A compared to Group B, at -29.3% vs -13.7% (

conclusionSildenafil citrate combined with tamsulosin improved LUTS, erectile function, and patient QoL more than tamsulosin monotherapy with the merit of a comparable safety profile in patients with LUTS/BPH.

Indexed as

Benign prostatic hyperplasia (BPH)BMI, body mass indexCONSORT, Consolidated Standards of Reporting TrialsED, erectile dysfunctionIIEF-5, five-item version of the International Index of Erectile Function questionnaireLower urinary tract symptoms (LUTS)NO, nitric oxideOD, once dailyPDE5-I, phosphodiesterase type 5 inhibitorQmax, maximum urinary flow rateQoL, quality of lifeRCT, randomised controlled trialSildenafilSMD, standardised mean differenceTamsulosin

Identifiers

PMID28275519
PMCPMC5329701
OpenAlexW2567433160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.